Most Read Articles
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

14 Aug 2019
Progressive lipolysis may be reduced via the improved antilipolytic effect in adipose tissue, which leads to a reduction in future weight loss caused by sodium-glucose cotransporter 2 inhibitors (SGLT2is) in patients with type 2 diabetes (T2D), suggests a recent study.
06 Aug 2019
Maternal prepregnancy obesity is associated with earlier age at voice break, pubic hair development, axillary hair and acne in sons, as well as with earlier age at menarche, breast development, pubic hair development, axillary hair and acne in daughters, a study has found. These associations appear to be mediated by higher childhood body mass index in sons and partly so in daughters.
15 Feb 2018
Long-term treatment with dual-release hydrocortisone (DR-HC) appears to produce favourable effects on insulin secretion and sensitivity in patients with prediabetes, according to a study. The treatment also confers benefits for metabolic and anthropometric parameters.

Product Highlight - Invokana

16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
  • INVOKANA demonstrated statistically significant glycated haemoglobin A1c (HbA1c) reductions and helped more patients achieve the ADA-recommended HbA1c goal of <7%1,4.
  • Only Invokana 300 mg demonstrated greater reductions in vs HbA1c sitagliptin 100 mg2.
  • INVOKANA results in the excretion of approximately 77 grams to 119 grams of glucose per day3.
  • INVOKANA provided greater reductions in body weight and systolic blood pressure vs placebo3.
  • INVOKANA showed good tolerability profile with the following most common adverse reactions – female genital mycotic infection, urinary tract infection (UTI) and increased urination3.
References:
1. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab.2013;15(4):372-382.
2. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508-2515.
3. Invokana_Approved Prescribing Information_Malaysia_EU SmPC vJan2016.
4: American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016; 39(Supplement 1): S39-S46.

Further information is available in Section 11b, New In This Issue and mims.com
Full prescribing information is available upon request.

MKT-CAN-MY-0026Creation Date: October 2016

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

14 Aug 2019
Progressive lipolysis may be reduced via the improved antilipolytic effect in adipose tissue, which leads to a reduction in future weight loss caused by sodium-glucose cotransporter 2 inhibitors (SGLT2is) in patients with type 2 diabetes (T2D), suggests a recent study.
06 Aug 2019
Maternal prepregnancy obesity is associated with earlier age at voice break, pubic hair development, axillary hair and acne in sons, as well as with earlier age at menarche, breast development, pubic hair development, axillary hair and acne in daughters, a study has found. These associations appear to be mediated by higher childhood body mass index in sons and partly so in daughters.
15 Feb 2018
Long-term treatment with dual-release hydrocortisone (DR-HC) appears to produce favourable effects on insulin secretion and sensitivity in patients with prediabetes, according to a study. The treatment also confers benefits for metabolic and anthropometric parameters.